{"name":"Idera Pharmaceuticals, Inc.","slug":"idera-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"IMO-2125","genericName":"IMO-2125","slug":"imo-2125","indication":"Advanced solid tumors","status":"phase_2"}]},{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"IMO-8400 Regimen 2","genericName":"IMO-8400 Regimen 2","slug":"imo-8400-regimen-2","indication":"Moderate to severe atopic dermatitis","status":"phase_2"}]}],"pipeline":[{"name":"IMO-2125","genericName":"IMO-2125","slug":"imo-2125","phase":"phase_2","mechanism":"IMO-2125 is a synthetic oligonucleotide that acts as a TLR9 agonist, stimulating the innate immune system.","indications":["Advanced solid tumors"],"catalyst":""},{"name":"IMO-8400 Regimen 2","genericName":"IMO-8400 Regimen 2","slug":"imo-8400-regimen-2","phase":"phase_2","mechanism":"IMO-8400 is a small molecule inhibitor of IRAK4, a key kinase in the Toll-like receptor signaling pathway.","indications":["Moderate to severe atopic dermatitis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxQZ0kxemFfZ3NoUDE0cGNBS040Ynh3d0t2Z0V5V2Z0QlVnRnBDMnFDcG9oRGFMNXF5NHZRNE0zb0NDZ2Q2ZUhuLXluSG96UldudEgxVlV6XzN3bm1jRTh2RmVjQ0lyQVlTWjh5eTRldzIxNHBhWXhNZGkxckpJVlBxYUpLSTBLVklMakRTV2NCZWNZWTM1YnJhUUVMUnJ6OUV2TWxTUFoxMjlQTGUxVFE4NkI3cUtnZTBkQkhZMXJFZWtRaV9MX2dkSzdrOE9qcjBteUp6aGFQTmd3WXJUMWlGSjdoUXBQRHRTVFMxcGJ1SGU1ZDktaGMtWTZzRG8?oc=5","date":"2026-03-12","type":"pipeline","source":"GlobeNewswire","summary":"Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer - GlobeNewswire","headline":"Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOa1lGWTFpZVh1UWhjWDFiMGFHZzA5eHd6ZGdsdWdtdmZBQnQ3ejF4Ml9ZZWpLUDliZVNTb2tQR0JhemYxTHRmU0tnbU1FMmZoZ0hMNE1GT1d1X2NORG5iakhDdVdubVRNZlpiM3JYMWhDNHZ1UGM1VTBWdlI5cmJTYmZFdGszalI0WEw4b2RaZGhnMFJyQVozQlhJV3FkcVJEbVdEVVlSMzc?oc=5","date":"2026-03-12","type":"pipeline","source":"Stock Titan","summary":"Helus Pharma (CYBN) appoints Jill Conwell as Chief People Officer - Stock Titan","headline":"Helus Pharma (CYBN) appoints Jill Conwell as Chief People Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxPMUw4bUdpR2F1emNkQ0dIWHVlMVJWV2ZIU0EweG1HeWFhWTV5bjlYMnkxeTd0Sm1jVDJEQmY3NVNoSHh5cEZTZThWUExPbnZJSzNVNjY5N01tSlJPS0I1UTEzelNPNGRKZUx6cVRkenAwbkdEeHpRWnhxZUh2cGJHOWZTak1NRUpGU19hbzNSMDBZWmo2UlJqdnFBeEM5OFN2WFd6SjFHMU01WVJVZDJMVWVZaDhsZGRBWGotaHU3UFM3Njg?oc=5","date":"2026-03-12","type":"pipeline","source":"TipRanks","summary":"Helus Pharma Adds Chief People Officer as Mental Health Pipeline Advances - TipRanks","headline":"Helus Pharma Adds Chief People Officer as Mental Health Pipeline Advances","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxQMVktWkJSNF9Bb05rbTdMWWNjZl9WaF9jcXR4MUlkeU9OZUxTcHRLSkY5VUNSM0JKS2pCWVZ1cldKQ2NyZzZjV0xKbFNRaDg4WDNBXzQwQ0lXb1FiM3BiVmpfZ0s2cy01T04wOHRSR0ctY1BWVlBwYTFMOFZOM1J0NlowZ0pQMHZuTFZ3UTltSUxRRHZmaE1uM29lcndmaDJsZkhlVkpoUW5HLTFNTUFFYTE5SUNWRWN4TW1DUkFn?oc=5","date":"2024-02-26","type":"pipeline","source":"Healio","summary":"Applying moisturizer before HP/TAZ for psoriasis may improve tolerability - Healio","headline":"Applying moisturizer before HP/TAZ for psoriasis may improve tolerability","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxNdTh2LTQyTVc5S2RsWU14RUFIZ3p2VTROcHZ5N2I3MTJwcEVBZjMxZnRqS0R5cmJkMTc0XzEzOGNrc1BXZGpuZWJpUHBnMnJPTGMzV2pCbU5GaEJuN0gwaHVJTFAyWlNYTUF2MXIxTTh3d0tyZW16QmpxYnJNTlQtOS1Wd1h2VEU?oc=5","date":"2022-09-29","type":"deal","source":"Yahoo Finance","summary":"Idera Pharma Acquires Rare Disease Player, Names New CEO - Yahoo Finance","headline":"Idera Pharma Acquires Rare Disease Player, Names New CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxQbEMyQ0RoNkozcWdodlRfZ2p2c0dPVDM0dURMcXozWHZWekVpbXFzSndYMmVtUjhEYnVWU213TGI1eDV2MFg1YmNjU0tVeDhiYkFRU0RiZGtHSkNtM3YyRFI2YmUtZWUxeG41UnZJbThTaW8wcUZITjNYbFFYQkM1M2tPdG5pZUQyLWo2RWE1QW8wbF80OFY4UHhwRFdUQ0V0SVdyNWxWczZoTEU2ZVlTdjZsNmVFeVFFRjNSSWNBTXlZUQ?oc=5","date":"2022-09-29","type":"deal","source":"fiercebiotech.com","summary":"Good Idera: Pharma buys rare-disease-focused Aceragen in all-stock deal to keep money flowing - fiercebiotech.com","headline":"Good Idera: Pharma buys rare-disease-focused Aceragen in all-stock deal to keep money flowing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxOYml0YnhpWnRMeWZpXzJkWWJhRGJyb1FTQ1lael9tUmxMejhQSkVhNjBCLVItNHhxbGFUT3BFbUM2UmZhNDZLcjluWHpGaS1fbEtrdjA5VHhUQ0Z6MkU2ZlkyZm5rcHYtXzd4b2JabjVLMmR4RW80SWdzSzhicnBFZU9ZR1ZvcDJSM25SS29aTGl1aGdGZ3lmclNtMTJxYjV0QklKUjdwWUxDUQ?oc=5","date":"2022-04-19","type":"deal","source":"MedCity News","summary":"Regeneron captures new piece for cancer with $250M Checkmate Pharma buyout - MedCity News","headline":"Regeneron captures new piece for cancer with $250M Checkmate Pharma buyout","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTFBzenVJOFJlSTAzcEs4dEhXeWtqYnJMVmxUTkx6bXdtdWJGYzlDUFBxRXQ1eWlWS3ZrSExfdUNWVHMtcVlmOG5mZFhmTVpYWjk5Z3c0Wl9UVDRIVjF5WFlZRFh6eUZEclRTYXV5RUlvdw?oc=5","date":"2022-01-12","type":"pipeline","source":"Pharma Voice","summary":"Talent Pool - Pharma Voice","headline":"Talent Pool","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTFBLNTdKT3NKaEZjbzFhSzNtOEJDUTVaVDlnREFNU1RqWmtPN3JvY3dURXJBZHRyNmtveW5GQzhuaDFRWFZ1TDc2ZFFyMXk2US1s?oc=5","date":"2021-09-15","type":"pipeline","source":"The Motley Fool","summary":"Idera Pharmaceuticals - IDRA - Stock Price & News - The Motley Fool","headline":"Idera Pharmaceuticals - IDRA - Stock Price & News","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxOSEF5dnBvN2l0UFB1M21KX3NGUUUyQnUzRzhNY0xZV3MtVUlCR1M2QUV5N0VKN2QxS1A5UlhLaVlsQVl2cXc3XzVkVGRZd2Y0ck1aM2tzcXk2Rmx5QmdZOWotZjZpWl9nQjNYM3pXanpmbEZZT0NZQzA4ZHlrU3hEaDZnMGV4WnlHYi1FempQSVJ3UENO?oc=5","date":"2018-07-11","type":"pipeline","source":"BioSpace","summary":"Idera Pharma and BioCryst Pharma Get a Divorce Before the Wedding - BioSpace","headline":"Idera Pharma and BioCryst Pharma Get a Divorce Before the Wedding","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPTDlxelBFVHk5UU9ENkEtSm1maEhFeVh6UnJBbW41eG9faWpBdWtkR2czR1E4dHAyVVRzcnJSWVpYR0IxdF84Z1MxQkxCZjNwZmhIQUNnUFU0bkx6a0F3S0JJdnFjZk5ZUTFBU1hZaW53bVZwUTIzQmpUY0hrUElqTjRfeUV0QWZsSlU0YmRpdUxMdHViZFNTTzFKd2N1MW00NFV3Njc5UjZNb2JFVzQ5TA?oc=5","date":"2018-02-20","type":"pipeline","source":"Investing News Network","summary":"5 Pharmaceutical NASDAQ Micro-Cap Stocks - Investing News Network","headline":"5 Pharmaceutical NASDAQ Micro-Cap Stocks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTFBzaXE2T3ZaY3BKajNZY3JONXFYMWN5clhia2pGMEE5Qi1VUTNDWWxUcGVqcFBFUHNpc3RRbXZvd09NMVhOSlkwaWluS3BySlNLQ3J2Rjg3NHl3LTVLQ1lwa2szT242Ri1qQVk4VC1jSDc2QmNVbGVXUF9saEs?oc=5","date":"2016-11-28","type":"pipeline","source":"BioPharma Dive","summary":"Idera sells licensing rights to shelved autoimmune drug - BioPharma Dive","headline":"Idera sells licensing rights to shelved autoimmune drug","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}